PARAGON

• Research type

  Research Study

• Full title

  PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms

• IRAS ID

  75407

• Contact name

  Richard Edmondson

• Sponsor organisation

  NHS Greater Glasgow & Clyde

• Eudract number

  2011-000501-52

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  The purpose of this study is to see if a hormonal treatment called Anastrazole can be effective at treating some specific types of gynaecological cancers. Anastrazole is a drug which can prevent tumour cells from responding to hormones, specifically oestrogen. We already know that many types of gynaecological cancers contain the oestrogen receptor meaning that oestrogen probably makes the tumours progress and so blocking this should make the tumour growth slow or even reverse the growth tumour. Anastrazole has already been tested in breast cancer where it has been shown to be effective and is now used as part of routine clinical care. Some small studies have already been carried out in some gynaecological cancers which suggest that Anastrazole may be effective in these types of cancers too and in this study we want to see whether this is true.

• REC name

  North East - Newcastle & North Tyneside 1 Research Ethics Committee

• REC reference

  11/NE/0214

• Date of REC Opinion

  7 Dec 2011

• REC opinion

  Further Information Favourable Opinion